Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.
Vedanta Biosciences is developing its microbiome therapy with support from the Biomedical Advanced Research and Development Authority. Under terms of that contract, the positive Phase 2 results in preventing recurrent C. diff infection trigger a $23.8 million payment.
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Seres Therapeutics had a rough 2016, but it's optimistic that those hard-earned lessons could now help it succeed. Following discussions with FDA, it has moved into a pivotal Phase 3 trial in recurrent C. difficile infections.
Cambridge-based Seres Health, a contender in the haute field of microbiome therapeutics, just hauled in a $48 million Series C round. The startup’s developing biologics that target recurrent C. difficile infections – a real nuisance in the realm of hospital-acquired infections. The company plans to use the funding to advance its lead candidate, SER-109, into Phase 3 clinical trials. If approved, Seres’ […]
Among patients with community-associated Clostridium difficile infection, more than a third had not used antibiotics in the 12 weeks prior to diagnosis and more than half reported limited or no health care contact over the same period. To assess possible sources of infection, Dr. Amit S. Chitnis and his colleagues at the U.S. Centers for […]